{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:51:13Z","timestamp":1792464673315,"version":"4.5.0"},"reference-count":58,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Little is known about opioid and gabapentinoid (OPI\u2010GABA) use duration and dose patterns\u2019 associations with adverse outcome risks. We examined associations between OPI\u2010GABA dose and duration trajectories and subsequent drug overdose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>US Medicare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Using a 5% sample (2011\u201316), we identified 71\u2009005 fee\u2010for\u2010service Medicare beneficiaries with fibromyalgia, low back pain, neuropathy and\/or osteoarthritis initiating OPIs and\/or GABAs [mean age\u00a0\u00b1\u00a0standard deviation (SD)\u00a0=\u00a065.5\u00a0\u00b1\u00a014.5\u00a0years, female\u00a0=\u00a068.1%, white\u00a0=\u00a076.8%].<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Group\u2010based multi\u2010trajectory models identified distinct OPI\u2010GABA use patterns during the year of OPI and\/or GABA initiation, based on weekly average standardized daily dose (i.e. OPIs\u00a0=\u00a0morphine milligram equivalent, GABAs\u00a0=\u00a0minimum effective daily dose). We estimated models with three to 12 trajectories and selected the best model based on Bayesian information criterion (BIC) and Nagin's criteria. We estimated risk of time to first drug overdose diagnosis within 12\u00a0months following the index year, adjusting for socio\u2010demographic and health factors using inverse probability of treatment weighted multivariable Cox proportional hazards models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>We identified 10 distinct trajectories (BIC\u00a0=\u00a0\u20131\u2009176\u2009954; OPI\u2010only\u00a0=\u00a03, GABA\u2010only\u00a0=\u00a03, OPI\u2010GABA\u00a0=\u00a04). Compared with OPI\u2010only early discontinuers (40.6% of the cohort), 1\u2010year drug overdose risk varied by trajectory group: consistent low\u2010dose OPI\u2010only users [16.6%; hazard ratio (HR)\u00a0=\u00a01.47, 95% confidence interval (CI)\u00a0=\u00a01.19\u20131.82], consistent high\u2010dose OPI\u2010only users (1.8%; HR\u00a0=\u00a04.57, 95% CI\u00a0=\u00a02.99\u20136.98), GABA\u2010only early discontinuers (12.5%; HR\u00a0=\u00a01.39, 95% CI\u00a0=\u00a01.09\u20131.77), consistent low\u2010dose GABA\u2010only users (11.0%; HR\u00a0=\u00a01.44, 95% CI\u00a0=\u00a01.12\u20131.85), consistent high\u2010dose GABA\u2010only users (3.1%; HR\u00a0=\u00a01.43, 95% CI\u00a0=\u00a00.94\u20132.17), early discontinuation of OPIs and consistent low\u2010dose GABA users (6.9%; HR\u00a0=\u00a01.24, 95% CI\u00a0=\u00a00.90\u20131.69), consistent low\u2010dose OPI\u2010GABA users (3.4%; HR\u00a0=\u00a02.49, 95% CI\u00a0=\u00a01.76\u20133.52), consistent low\u2010dose OPI and high\u2010dose GABA users (3.2%; HR\u00a0=\u00a02.46, 95% CI\u00a0=\u00a01.71\u20133.53) and consistent high\u2010dose OPI and moderate\u2010dose GABA users (0.9%; HR\u00a0=\u00a07.22, 95% CI\u00a0=\u00a04.46\u201311.69).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Risk of drug overdose varied substantially among US Medicare beneficiaries on different use trajectories of opioids and gabapentinoids. High\u2010dose opioid\u2010only users and all consistent opioid and gabapentinoid users (regardless of doses) had more than double the risk of subsequent drug overdose compared with opioid\u2010only early discontinuers.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.15189","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T14:04:50Z","timestamp":1594389890000},"page":"819-830","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Dual\u2010trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9568-1325","authenticated-orcid":false,"given":"Lili","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy University of Arizona  Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-5138","authenticated-orcid":false,"given":"Sandipan","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy University of Arizona  Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-550X","authenticated-orcid":false,"given":"C. Kent","family":"Kwoh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, College of Medicine University of Arizona  Tucson AZ USA"},{"name":"University of Arizona Arthritis Center, College of Medicine, University of Arizona  Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Tighe","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology College of Medicine, University of Florida, Gainesville  FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5022-5430","authenticated-orcid":false,"given":"Gary M.","family":"Reisfield","sequence":"additional","affiliation":[{"name":"Divisions of Addiction Medicine and Forensic Psychiatry, Departments of Psychiatry and Anesthesiology College of Medicine, University of Florida, Gainesville  FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy University of Utah  Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Slack","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, College of Pharmacy University of Arizona  Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-5497","authenticated-orcid":false,"given":"Debbie L.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy College of Pharmacy, University of Florida, Gainesville  FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9585-6340","authenticated-orcid":false,"given":"Ching\u2010Yuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy College of Pharmacy, University of Florida, Gainesville  FL USA"},{"name":"Center for Drug Evaluation and Safety College of Pharmacy, University of Florida, Gainesville  FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6590-4770","authenticated-orcid":false,"given":"Wei\u2010Hsuan","family":"Lo\u2010Ciganic","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy College of Pharmacy, University of Florida, Gainesville  FL USA"},{"name":"Center for Drug Evaluation and Safety College of Pharmacy, University of Florida, Gainesville  FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Micromedex\u00ae2.0, (electronic version)","author":"Gabapentin P.","year":"2019"},{"key":"e_1_2_9_3_1","unstructured":"Drugs@FDA: FDA Approved Drug Products. Available at:https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/(accessed 27 August 2018)."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7856"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.9.1021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14101272"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13324"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.08.430"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4230"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.013"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1136"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0595-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200007000-00035"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12538"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0530-3"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2016.303404"},{"key":"e_1_2_9_18_1","unstructured":"US Congressional Research Services (CRS).The SUPPORT for Patients and Communities Act (P.L.115\u2013271): Medicare Provisions. Washington DC: CRS;2019."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.180646"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S105613"},{"key":"e_1_2_9_22_1","unstructured":"Chronic Condition Data Warehouse (CCW).CCW Medicare Administrative Data User Guide [internet].2019. [cited June 2019]. Available at:https:\/\/www2.ccwdata.org\/web\/guest\/user-documentation(accessed 26 June 2019)."},{"key":"e_1_2_9_23_1","unstructured":"Kaiser Family Foundation.Medicare Advantage [internet].2019. [cited 4 April 2020]. Available at:https:\/\/www.kff.org\/medicare\/fact-sheet\/medicare-advantage\/(accessed 4 April 2020)."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0530-8"},{"key":"e_1_2_9_25_1","first-page":"447","article-title":"Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans","volume":"16","author":"Margolis J. M.","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.008"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2008.00204.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2017.11.022"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0968"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2010.11.031"},{"key":"e_1_2_9_31_1","unstructured":"Pharmacy Quality Alliance: Opioid Core Measure Set\u20102019. Alexandria VA: Pharmacy Quality Alliance; 2019."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0919"},{"key":"e_1_2_9_33_1","unstructured":"Center for Disease Control and Prevention (CDC). Guideline for Prescribing Opioids for Chronic Pain. Atlanta GA: CDC; 2016."},{"key":"e_1_2_9_34_1","unstructured":"Centers for Disease Control and Prevention (CDC).Calculating Total Daily Dose of Opioids for Safer Dosage. Atlanta GA: CDC. Available at:https:\/\/www.cdc.gov\/drugoverdose\/pdf\/calculating_total_daily_dose-a.pdf(accessed 26 June 2019)."},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","unstructured":"JonesB. L. NaginD. S.A Stata Plugin for Estimating Group\u2010Based Trajectory Models. Sociol Methods Res2013; 42: 608\u2013613.","DOI":"10.1177\/0049124113503141"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.04.010"},{"key":"e_1_2_9_37_1","article-title":"Group\u2010based multi\u2010trajectory modeling","author":"Daniel S. N.","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0049124106292364"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13270"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00006"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1514387"},{"key":"e_1_2_9_42_1","volume-title":"Area Health Resources Files (AHRF) 2013\u20102014","author":"US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Workforce","year":"2018"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2097"},{"key":"e_1_2_9_45_1","unstructured":"University of California Los Angeles (UCLA) Institute for Digital Research and Education.Testing the Proportional Hazard Assumption in Cox Models. Los Angeles CA: UCLA;2008.Available at:https:\/\/stats.idre.ucla.edu\/other\/examples\/asa2\/testing-the-proportional-hazard-assumption-in-cox-models\/(accessed 26 June 2019)."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3182984c1f"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.506"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15077"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.3077"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008007"},{"key":"e_1_2_9_54_1","first-page":"649","article-title":"The efficacy of preoperative Gabapentin in spinal surgery: a meta\u2010analysis of randomized controlled trials","volume":"20","author":"Han C.","year":"2017","journal-title":"Pain Physician"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011581"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.12965\/jer.1836420.210"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1390081"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-18"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13121"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fadd.15189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15189","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T19:53:10Z","timestamp":1693597990000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/add.15189"],"URL":"https:\/\/doi.org\/10.1111\/add.15189","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"2019-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}